Laboratory of Biomedical Genomics and Oncogenetics, Institut Pasteur de Tunis, BP 74, 13 Place Pasteur, Tunis 1002, Tunisia.
National Institute of Applied Science and Technology, University of Carthage, Tunis, Tunisia.
Biosci Rep. 2022 Sep 30;42(9). doi: 10.1042/BSR20220194.
Mitochondrial cytopathies, among which the Leigh syndrome (LS), are caused by variants either in the mitochondrial or the nuclear genome, affecting the oxidative phosphorylation process. The aim of the present study consisted in defining the molecular diagnosis of a group of Tunisian patients with LS. Six children, belonging to five Tunisian families, with clinical and imaging presentations suggestive of LS were recruited. Whole mitochondrial DNA and targeted next-generation sequencing of a panel of 281 nuclear genes involved in mitochondrial physiology were performed. Bioinformatic analyses were achieved in order to identify deleterious variations. A single m.10197G>A (p.Ala47Thr) variant was found in the mitochondrial MT-ND3 gene in one patient, while the others were related to autosomal homozygous variants: two c.1412delA (p.Gln471ArgfsTer42) and c.1264A>G (p.Thr422Ala) in SLC19A3, one c.454C>G (p.Pro152Ala) in SLC25A19 and one c.122G>A (p.Gly41Asp) in ETHE1. Our findings demonstrate the usefulness of genomic investigations to improve LS diagnosis in consanguineous populations and further allow for treating the patients harboring variants in SLC19A3 and SLC25A19 that contribute to thiamine transport, by thiamine and biotin supplementation. Considering the Tunisian genetic background, the newly identified variants could be screened in patients with similar clinical presentation in related populations.
线粒体细胞病,其中包括 Leigh 综合征(LS),是由线粒体或核基因组中的变异引起的,影响氧化磷酸化过程。本研究的目的是确定一组具有 LS 临床和影像学表现的突尼斯患者的分子诊断。招募了六名儿童,他们来自五个突尼斯家庭,具有 LS 的临床和影像学表现。进行了全线粒体 DNA 和一组 281 个与线粒体生理学相关的核基因的靶向下一代测序。为了识别有害的变异,进行了生物信息学分析。在一名患者的线粒体 MT-ND3 基因中发现了单个 m.10197G>A(p.Ala47Thr)变异,而其他患者则与常染色体纯合变异有关:SLC19A3 中的两个 c.1412delA(p.Gln471ArgfsTer42)和 c.1264A>G(p.Thr422Ala),SLC25A19 中的 c.454C>G(p.Pro152Ala)和 ETHE1 中的 c.122G>A(p.Gly41Asp)。我们的发现表明基因组研究在提高近亲人群中 LS 诊断的有用性,并进一步允许对携带 SLC19A3 和 SLC25A19 变异的患者进行治疗,这些变异有助于硫胺素转运,通过硫胺素和生物素补充。考虑到突尼斯的遗传背景,新发现的变异可以在相关人群中具有类似临床表现的患者中进行筛选。